Science and Technology
Historically, the equipment used in molecular diagnosis has presented challenges in both operation and maintenance, limiting their use to a small group of highly trained specialists.
Our cutting-edge proposal breaks through this barrier by offering revolutionary technology that simplifies the process, allowing a greater number of laboratories, hospitals, and healthcare professionals to access molecular tests with unprecedented confidence and precision.
Introducing IRIS®
Developments
Genetic
TH IRIS® Exam Kit
Hereditary Thrombophilia
It is estimated that in Argentina, more than 60,000 people suffer from this condition each year. The overall in-hospital mortality rate in Argentina for hospitalized patients with Venous Thromboembolism (VTE) is 19%.
VTE is a multifactorial disease resulting from the combination of genetic factors (Hereditary Thrombophilia, TH), environmental factors, and acquired conditions that determine individual clinical expression.
The TH IRIS® Exam kit, based on IRIS® Technology, allows for the analysis of the main genetic variations associated with TH. This kit comes in two versions: a two-gene version (F2/F5) and a five-gene version (Austral version). The two-gene version is approved by ANMAT (the regulatory agency in Argentina, similar to the FDA in the US) for in vitro diagnostic (IVD) use.
Infectious
- Accurate diagnosis of the etiological agent causing acute.
- Respiratory infection implementing the most appropriate therapy.
- Understanding the prognosis and progression of the infection.
- Separating hospitalized patients with different viruses or bacteria.
- Controlling the dissemination of intrahospital pathogens.
- Identifying antiviral resistance.
- Conducting epidemiological studies on agents affecting the population.
Pharmacogenomics
Equipment
Software
IRIS® All in One
Fully automated and cloud-integrated
- Only platform capable of meeting the needs of all laboratories: Pharmacogenomics, Infectious and Genetic Diseases.
- Versatile: capable of simultaneously diagnosing multiple genetic biomarkers per sample.
- Felxible: efficiently works with just 15 patient samples, testing for 15 different diseases
- Simple easy to use and maintain.
Platform under development. Available in 2025.